To read the full story
Related Article
- Mochida’s EPA Drug Epadel S Wins Approval in China
January 9, 2026
- Vietnam Clears Epadel for Import, Launch Planned via Partner: Mochida/Meiji
June 20, 2025
- Mochida, Meiji Expand Epadel Sales Collab to ASEAN, Taiwan
September 2, 2024
- Mochida Files EPA Agent Epadel in China
July 3, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
- Meiji Scoops Up Marketing Rights for Mochida’s Epadel in Vietnam
April 7, 2020
- Epadel to Enter Clinical Study in China: Mochida, Sumitomo Dainippon
July 18, 2018
BUSINESS
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
- Toho Backs AI Startup Developing Laxative-Free Colonoscopy
November 16, 2026
- KM Biologics Files Japan’s Potential First Therapy for Factor X Deficiency
November 16, 2026
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





